Evidence map›Paper›PMID 38853901›Full record

ArticlebioRxiv : the preprint server for biology2024

Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition.

Chuwei Lin, Catherine M Sniezek, Christopher D McGann, Rashmi Karki, Ross M Giglio, Benjamin A Garcia, José L McFaline-Figeroa, Devin K Schweppe

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Chuwei LinGenome Sciences, University of Washington, Seattle, WA 98105, USA.ORCID 0000-0002-8640-5695
Catherine M SniezekGenome Sciences, University of Washington, Seattle, WA 98105, USA.
Christopher D McGannGenome Sciences, University of Washington, Seattle, WA 98105, USA.
Rashmi KarkiDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ross M GiglioBiomedical Engineer, Columbia University, New York, NY 10027, USA.
Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
José L McFaline-FigeroaBiomedical Engineer, Columbia University, New York, NY 10027, USA.
Devin K SchweppeGenome Sciences, University of Washington, Seattle, WA 98105, USA.

Funding

Technology for evaluating drug-binding responses to small-molecule perturbationR35GM150919 · NIGMS · UNIVERSITY OF WASHINGTON · PI Devin Karl Schweppe · 2023 to 2026
$1.6M
NIGMS NIH HHS R35 GM150919
6 · The paper itself

Abstract

Epigenetic inhibitors exhibit powerful antiproliferative and anticancer activities. However, cellular responses to small-molecule epigenetic inhibition are heterogenous and dependent on factors such as the genetic background, metabolic state, and on-/off-target engagement of individual small-molecule compounds. The molecular study of the extent of this heterogeneity often measures changes in a single cell line or using a small number of compounds. To more comprehensively profile the effects of small-molecule perturbations and their influence on these heterogeneous cellular responses, we present a molecular resource based on the quantification of chromatin, proteome, and transcriptome remodeling due to histone deacetylase inhibitors (HDACi) in non-isogenic cell lines. Through quantitative molecular profiling of 10,621 proteins, these data reveal coordinated molecular remodeling of HDACi treated cancer cells. HDACi-regulated proteins differ greatly across cell lines with consistent (JUN, MAP2K3, CDKN1A) and divergent (CCND3, ASF1B, BRD7) cell-state effectors. Together these data provide valuable insight into cell-type driven and heterogeneous responses that must be taken into consideration when monitoring molecular perturbations in culture models.

Identifiers

PMID38853901
PMCPMC11160595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.